Advancing Next-Generation TCEs with AI-Guided Drug Design
- Exploring why new TCE designs such as dual targeting or avidity-based formats are required to overcome the challenges to TCE efficacy posed by solid tumors
- Building a deeper understanding of the affinity and epitope requirements that maximize tumor selectivity which will be critical to unlock the potential of dual targeting TCEs
- AI integration is profoundly impacting therapeutic discovery, enabling delivery of optimized candidates at breakthrough speed